NCT00441506

Brief Summary

Critically ill children are often sedated in order to relieve them from anxiety and discomfort, and to facilitate their care. There is little information on the effects of prolonged and continuous use of sedatives and analgesic agents in critically ill children. In adult intensive care unit (ICU) patients, daily interruption of sedative infusions accelerates recovery resulting in a reduction in the average duration of mechanical ventilation of 2.4 days as well as a reduction in average ICU length of stay of 3.5 days. These results were achieved without an increased rate of adverse events potentially linked to less sedation and associated with a reduction of common complications of critical illness and without negative psychological effects. It is unknown whether these results can be extrapolated to critically ill children. Moreover, the possible risk of complications associated with less sedation, such as accidental self-extubation, is probably higher in children. Also, the need for intermittent bolus administrations in children treated with intermittent sedation could nullify the reduction in the use of sedatives. It is unknown if daily interruption of sedatives is feasible in critically ill children. The researchers studied the effects of daily interruption of sedatives in critically ill children on the total amount of sedatives used and risks of complications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2004

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2004

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2006

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2006

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 1, 2007

Completed
Last Updated

August 24, 2010

Status Verified

February 1, 2007

Enrollment Period

1.6 years

First QC Date

February 28, 2007

Last Update Submit

August 23, 2010

Conditions

Keywords

interruptioncritically illsedationpediatricscritically ill, ventilated children

Outcome Measures

Primary Outcomes (4)

  • amount of (near) incidents

    Until extubation or 28 days

  • total amount of sedatives administered

    Until extubation or 28 days

  • time to wake up (after sedation is stopped), comfort scale

    Until extubation or 28 days

  • BIS monitoring

    Until extubation or 28 days

Secondary Outcomes (2)

  • time on ventilator

    Until extubation or 28 days

  • LOS on ICU

    Until extubation or 28 days

Interventions

Eligibility Criteria

AgeUp to 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Intubated and mechanically ventilated for \> 24 hours
  • Expect further mechanical ventilation for \> 48 hours
  • Receiving midazolam and morphine for sedation
  • Written informed consent given by parents

You may not qualify if:

  • Transfer from an outside institution where sedatives had been administered
  • Neuromuscular blockers
  • Metabolic disease
  • Neuromuscular disease
  • Encephalopathy
  • Epilepsy
  • Pulmonary hypertension
  • Neurotrauma
  • Raised intracranial pressure
  • Life expectancy less than a month/infaust prognosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radboud University Nijmegen Medical Center

Nijmegen, Gelderland, 6500HB, Netherlands

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Peter Pickkers, MD, PhD

    Radboud University Medical Center

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 28, 2007

First Posted

March 1, 2007

Study Start

November 1, 2004

Primary Completion

June 1, 2006

Study Completion

July 1, 2006

Last Updated

August 24, 2010

Record last verified: 2007-02

Locations